James E. Hilbert

1.7k total citations
29 papers, 1.1k citations indexed

About

James E. Hilbert is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Neurology. According to data from OpenAlex, James E. Hilbert has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cellular and Molecular Neuroscience, 17 papers in Molecular Biology and 15 papers in Neurology. Recurrent topics in James E. Hilbert's work include Genetic Neurodegenerative Diseases (20 papers), Parkinson's Disease Mechanisms and Treatments (12 papers) and Mitochondrial Function and Pathology (6 papers). James E. Hilbert is often cited by papers focused on Genetic Neurodegenerative Diseases (20 papers), Parkinson's Disease Mechanisms and Treatments (12 papers) and Mitochondrial Function and Pathology (6 papers). James E. Hilbert collaborates with scholars based in United States, Sweden and Germany. James E. Hilbert's co-authors include Richard T. Moxley, Gary A. Sforzo, T. Swensen, Charles A. Thornton, William B. Martens, Elizabeth Luebbe, Michael McDermott, Mark H. Greene, Jean M. Bidlack and Wennan Xiong and has published in prestigious journals such as JAMA, PLoS ONE and Neurology.

In The Last Decade

James E. Hilbert

29 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James E. Hilbert United States 20 674 590 363 119 107 29 1.1k
Gian Luca Vita Italy 17 129 0.2× 746 1.3× 74 0.2× 88 0.7× 27 0.3× 61 1.0k
Torsten Grehl Germany 16 245 0.4× 287 0.5× 588 1.6× 12 0.1× 17 0.2× 37 975
Yuhao Huang Taiwan 19 204 0.3× 315 0.5× 274 0.8× 12 0.1× 7 0.1× 60 1.3k
Miranda Mladinić Italy 18 313 0.5× 284 0.5× 88 0.2× 8 0.1× 12 0.1× 40 710
Pía M. Vidal Chile 17 227 0.3× 278 0.5× 61 0.2× 21 0.2× 7 0.1× 29 940
Dingding Shen China 16 293 0.4× 348 0.6× 111 0.3× 29 0.2× 6 0.1× 36 693
Christian Bonde Denmark 17 351 0.5× 222 0.4× 73 0.2× 32 0.3× 4 0.0× 62 1.2k
Mitsuya Morita Japan 18 158 0.2× 507 0.9× 1.2k 3.3× 14 0.1× 16 0.1× 64 1.7k
Nai-Kui Liu United States 15 226 0.3× 371 0.6× 79 0.2× 10 0.1× 10 0.1× 16 789
Cinzia Brandoli United States 9 175 0.3× 226 0.4× 30 0.1× 18 0.2× 31 0.3× 14 558

Countries citing papers authored by James E. Hilbert

Since Specialization
Citations

This map shows the geographic impact of James E. Hilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Hilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Hilbert more than expected).

Fields of papers citing papers by James E. Hilbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Hilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Hilbert. The network helps show where James E. Hilbert may publish in the future.

Co-authorship network of co-authors of James E. Hilbert

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Hilbert. A scholar is included among the top collaborators of James E. Hilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Hilbert. James E. Hilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamel, Johanna, Michael McDermott, James E. Hilbert, et al.. (2022). Milestones of progression in myotonic dystrophy type 1 and type 2. Muscle & Nerve. 66(4). 508–512. 4 indexed citations
2.
Schoser, Benedikt, Federica Montagnese, Guillaume Bassez, et al.. (2019). Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurology Clinical Practice. 9(4). 343–353. 35 indexed citations
3.
Higgs, Cecilia, James E. Hilbert, Libby Wood, et al.. (2019). Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries. Frontiers in Neurology. 10. 1071–1071. 2 indexed citations
4.
Hilbert, James E., Richard J. Barohn, Paula R. Clemens, et al.. (2017). High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. Neurology. 89(13). 1348–1354. 37 indexed citations
5.
Gadalla, Shahinaz M., et al.. (2017). Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy. European Journal of Neurology. 24(5). 713–718. 12 indexed citations
6.
Miller, David, Chester C. Wood, Eric D. Bateman, et al.. (2017). A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. Allergy and Asthma Proceedings. 38(2). 157–164. 22 indexed citations
7.
Conn, Kelly M., Joanne Smith, Andrew J. Walker, et al.. (2016). Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy. Journal of Neurology. 263(12). 2528–2537. 7 indexed citations
8.
Hilbert, James E., Tetsuo Ashizawa, John Day, et al.. (2013). Diagnostic odyssey of patients with myotonic dystrophy. Journal of Neurology. 260(10). 2497–2504. 72 indexed citations
9.
Kalman, Lisa V., Jack Tarleton, Madhuri Hegde, et al.. (2013). Development of a Genomic DNA Reference Material Panel for Myotonic Dystrophy Type 1 (DM1) Genetic Testing. Journal of Molecular Diagnostics. 15(4). 518–525. 14 indexed citations
10.
Gadalla, Shahinaz M., Ruth M. Pfeiffer, Sigurður Y. Kristinsson, et al.. (2013). Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. PLoS ONE. 8(11). e79851–e79851. 25 indexed citations
11.
Moxley, Richard T., et al.. (2012). Correlates of tumor development in patients with myotonic dystrophy. Journal of Neurology. 259(10). 2161–2166. 36 indexed citations
12.
Gadalla, Shahinaz M., Marie Lund, Ruth M. Pfeiffer, et al.. (2011). Cancer Risk Among Patients With Myotonic Muscular Dystrophy. JAMA. 306(22). 2480–6. 89 indexed citations
13.
Hilbert, James E., John T. Kissel, Elizabeth Luebbe, et al.. (2011). If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemporary Clinical Trials. 33(2). 302–311. 49 indexed citations
14.
Heatwole, Chad, Katy Eichinger, Deborah I. Friedman, et al.. (2010). Open-Label Trial of Recombinant Human Insulin-like Growth Factor 1/Recombinant Human Insulin-like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1. Archives of Neurology. 68(1). 37–44. 40 indexed citations
15.
Mueller, Christine M., James E. Hilbert, William B. Martens, et al.. (2009). Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes & Control. 20(10). 2009–2020. 49 indexed citations
16.
Zhang, Ao, et al.. (2004). 2-Aminothiazole-Derived Opioids. Bioisosteric Replacement of Phenols. Journal of Medicinal Chemistry. 47(8). 1886–1888. 47 indexed citations
17.
Hilbert, James E., Gary A. Sforzo, & T. Swensen. (2003). The effects of massage on delayed onset muscle soreness. British Journal of Sports Medicine. 37(1). 72–75. 148 indexed citations
18.
Zhang, Ao, Wennan Xiong, Jean M. Bidlack, et al.. (2003). 10-Ketomorphinan and 3-Substituted-3-desoxymorphinan Analogues as Mixed κ and μ Opioid Ligands:  Synthesis and Biological Evaluation of Their Binding Affinity at Opioid Receptors. Journal of Medicinal Chemistry. 47(1). 165–174. 37 indexed citations
19.
Neumeyer, John L., Ao Zhang, Wennan Xiong, et al.. (2003). Design and Synthesis of Novel Dimeric Morphinan Ligands for κ and μ Opioid Receptors. Journal of Medicinal Chemistry. 46(24). 5162–5170. 71 indexed citations
20.
Myers, Ronald E., Sally W. Vernon, Anne‐Marie Carpenter, et al.. (1997). Employee response to a company-sponsored program of colorectal and prostate cancer screening.. PubMed. 21(4). 380–9. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gian Luca Vita Breakdown of academic impact, for papers by Torsten Grehl Breakdown of academic impact, for papers by Yuhao Huang Breakdown of academic impact, for papers by Miranda Mladinić Breakdown of academic impact, for papers by Pía M. Vidal Breakdown of academic impact, for papers by Dingding Shen Breakdown of academic impact, for papers by Christian Bonde Breakdown of academic impact, for papers by Mitsuya Morita Breakdown of academic impact, for papers by Nai-Kui Liu Breakdown of academic impact, for papers by Cinzia Brandoli
Rankless by CCL
2026